韩国军队环境下人腺病毒疫苗研发的成本效益分析
该研究从社会视角对韩国军队研发并接种人腺病毒疫苗进行成本效益分析,假设研发5年、第6年开始接种,基础情景为接种率100%、发病率0.02、疫苗效力95%、贴现率3%。第6年效益成本比为0.71,第7年起升至1.32,10年累计达2.72,敏感性分析结果一致,结论为第7年起具有成本效益。
要点
- 第6年效益成本比0.71,第7年起升至1.32,10年累计2.72。
- 基础情景假设接种率100%、发病率0.02、疫苗效力95%、贴现率3%。
- 敏感性分析结果与基础情景一致。
核心结论
- 成本效益分析表明,为韩国军队引入人腺病毒疫苗具有经济优势,从开始接种后的第7年起产生显著成本效益。
研究设计与样本
- 采用社会视角的成本效益分析,估算疫苗研发、生产和配送成本,假设研发期5年、第6年开始生产和接种,效益基于接种预防人腺病毒感染所节省的直接和间接成本,所有金额以2023年美元表示,并进行敏感性分析。
主要发现
- 基础情景(接种率100%、发病率0.02、疫苗效力95%、贴现率3%)下,第6年效益成本比为0.71,表明接种初期存在成本劣势。
- 第7年起效益成本比改善至1.32,表明从第7年起具有成本效益。
- 10年累计效益成本比达到2.72。
- 敏感性分析结果与基础情景一致。
关键数值与推荐
- 基础情景:接种率100%、发病率0.02、疫苗效力95%、贴现率3%。
- 第6年效益成本比0.71,第7年起1.32,10年累计2.72。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human adenovirus (HAdV) is a prevalent causative agent of acute respiratory disease (ARD) and is frequently responsible for outbreaks, particularly in military environments. Current vaccines do not effectively cover HAdV subtypes commonly found among Korean military personnel, highlighting the need for a new targeted vaccine. This study presents a cost-benefit analysis to evaluate the economic viability of developing and implementing such a vaccine within a military context. METHODS: We adopted a societal perspective for this cost-benefit analysis, which included estimating costs associated with vaccine development, production, and distribution over a projected timeline. We assumed a development period of five years, after which vaccine production and administration were initiated in the sixth year. The cost associated with vaccine development, production, and dispensation was considered. The benefits were calculated based on both direct and indirect cost savings from preventing HAdV infections through vaccination. All financial figures were expressed in 2023 US dollars. A sensitivity analysis was conducted to explore the impact of varying factors such as vaccination rate, incidence of infection, vaccine efficacy, and discount rate. RESULTS: For the base case scenario, we assumed a vaccination rate of 100 %, an incidence rate of 0.02, and a vaccine efficacy of 95 %, applying a 3 % discount rate. Initially, in the sixth year, the benefit-cost ratio stood at 0.71, suggesting a cost disadvantage at the onset of vaccination. However, this ratio improved to 1.32 in the following years, indicating a cost benefit from the seventh year onward. The cumulative benefit-cost ratio over a decade reached 2.72. The outcomes from the sensitivity analysis were consistent with these findings. CONCLUSION: Our cost-benefit analysis demonstrates that the introduction of an HAdV vaccine for the Korean military is economically advantageous, with substantial cost benefits accruing from the seventh year after the commencement of vaccination.
引用
- Eom J, Kim Y, Kim D, et al. Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting. Vaccine. 2024. PMID: 38806354. doi:10.1016/j.vaccine.2024.05.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。